These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19858774)

  • 1. Modern trends in mortality from meningococcal disease in Australia.
    Simpkins D; Wood N; Jelfs J; McIntyre PB; Menzies R; Lawrence G; Booy R
    Pediatr Infect Dis J; 2009 Dec; 28(12):1119-20. PubMed ID: 19858774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of meningococcal serogroup C conjugate vaccine in Scotland.
    Mooney JD; Christie P; Robertson C; Clarke SC
    Clin Infect Dis; 2004 Aug; 39(3):349-56. PubMed ID: 15307001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Acceptance of the new conjugate vaccines. Meningococcal and pneumococcal vaccines, in the cohort born in 1999, in the North Region of Portugal].
    De Queirós L; Castro L; Ferreira MC; Gonçalves G
    Acta Med Port; 2004; 17(1):49-53. PubMed ID: 15636727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2009 Apr; 35(ACS-3):1-40. PubMed ID: 19400026
    [No Abstract]   [Full Text] [Related]  

  • 5. Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians.
    Kafetzis DA; Stamboulidis KN; Tzanakaki G; Kourea Kremastinou J; Skevaki CL; Konstantopoulos A; Tsolia M
    Clin Microbiol Infect; 2007 May; 13(5):550-2. PubMed ID: 17378929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.
    Bettinger JA; Scheifele DW; Le Saux N; Halperin SA; Vaudry W; Tsang R;
    Pediatr Infect Dis J; 2009 Mar; 28(3):220-4. PubMed ID: 19209096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evolution of meningococcal disease in the community of Madrid. Effectiveness of antimeningococcal A+C vaccination].
    Gutiérrez Rodríguez MA; Ramírez Fernández R; García Gutiérrez J; Moreno Civantos A; Hernando García M; Arce Arnáez A; Sendra Gutiérrez JM; Bueno Vallejos R
    Rev Esp Salud Publica; 2000; 74(4):397-403. PubMed ID: 11031849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent trends in meningococcal epidemiology and current vaccine recommendations.
    Baltimore RS
    Curr Opin Pediatr; 2006 Feb; 18(1):58-63. PubMed ID: 16470164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine.
    Cardeñosa N; Domínguez A; Martínez A; Alvarez J; Pañella H; Godoy P; Minguell S; Camps N; Vázquez JA;
    Infection; 2003 Dec; 31(6):392-7. PubMed ID: 14735381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine.
    Macneil JR; Cohn AC; Zell ER; Schmink S; Miller E; Clark T; Messonnier NE;
    Pediatr Infect Dis J; 2011 Jun; 30(6):451-5. PubMed ID: 21206392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meningococcal vaccines: a neglected topic in travel medicine?
    Wilder-Smith A
    Expert Rev Vaccines; 2009 Oct; 8(10):1343-50. PubMed ID: 19803757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of bacterial meningitis in Niamey, Niger, 1981-96.
    Campagne G; Schuchat A; Djibo S; Ousséini A; Cissé L; Chippaux JP
    Bull World Health Organ; 1999; 77(6):499-508. PubMed ID: 10427935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meningococcal C conjugate vaccination recommendations for infants. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2007 Nov; 33(ACS-11):1-12. PubMed ID: 18064747
    [No Abstract]   [Full Text] [Related]  

  • 16. [Survey on vaccination strategies used in different Italian Regions, for the 7-valent conjugate pneumococcal, meningococcal C and varicella vaccines].
    D'Ancona F; Alfonsi V; Ciofi degli Atti ML
    Ig Sanita Pubbl; 2006; 62(5):483-92. PubMed ID: 17206224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.
    Larrauri A; Cano R; García M; Mateo Sd
    Vaccine; 2005 Jul; 23(32):4097-100. PubMed ID: 15908059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Meningococcal disease. new prevention strategies].
    Soult Rubio JA; Muñoz Sáez M; López Castilla JD
    An Esp Pediatr; 2001 Jan; 54(1):65-8. PubMed ID: 11181197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
    Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
    Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients.
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2005 Aug; 116(2):496-505. PubMed ID: 15995007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.